deltatrials
Completed OBSERVATIONAL NCT04543331

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (BLUE SKY)

OBservationaL stUdy to Evaluate Fluid reSolution and Effectiveness in Patients Receiving Beovu (Brolucizumab) Under KeY Treatment Schemes in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Sponsor: Novartis Pharmaceuticals

Interventions brolucizumab
Updated 24 times since 2020 Last updated: Nov 28, 2025 Started: Nov 5, 2020 Primary completion: Nov 17, 2025 Completion: Nov 17, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04543331, this observational or N/A phase trial focuses on Diabetic Macular Edema (DME) and Neovascular Age-related Macular Degeneration (nAMD) and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 24 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jul 2025 · 5 months · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

24 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed

    Status: Active Not RecruitingCompleted

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting

  3. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting

  4. Jul 2025 — Aug 2025 [monthly]

    Active Not Recruiting

  5. Feb 2025 — Jul 2025 [monthly]

    Active Not Recruiting

Show 19 earlier versions
  1. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting

  3. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting

  4. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting

    Status: RecruitingActive Not Recruiting

  5. Feb 2024 — Apr 2024 [monthly]

    Recruiting

  6. Jan 2024 — Feb 2024 [monthly]

    Recruiting

  7. Dec 2023 — Jan 2024 [monthly]

    Recruiting

  8. Nov 2023 — Dec 2023 [monthly]

    Recruiting

  9. Sep 2023 — Nov 2023 [monthly]

    Recruiting

  10. May 2023 — Sep 2023 [monthly]

    Recruiting

  11. Sep 2022 — May 2023 [monthly]

    Recruiting

  12. Jun 2022 — Sep 2022 [monthly]

    Recruiting

  13. Jun 2021 — Jun 2022 [monthly]

    Recruiting

  14. May 2021 — Jun 2021 [monthly]

    Recruiting

  15. Apr 2021 — May 2021 [monthly]

    Recruiting

  16. Feb 2021 — Apr 2021 [monthly]

    Recruiting

  17. Jan 2021 — Feb 2021 [monthly]

    Recruiting

  18. Dec 2020 — Jan 2021 [monthly]

    Recruiting

    Status: Not Yet RecruitingRecruiting

  19. Oct 2020 — Dec 2020 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .